buyWeak
Venrock Healthcare Capital Partners III, L.P. bought $622k of KALV
owner at KalVista Pharmaceuticals, Inc.. 70,023 shares at an average of $8.88, traded Jan 30, 2025, filed Feb 3, 2025.
Conviction score
27Value
$622k
70,023 shares
Holdings after
5,012,796
+1% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +12Role10% owner
- +20Trade size$622k at market
- 0Relative to holdingsHoldings up 1.4%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001415889-25-002809, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 30, 2025 | POpen-market purchase Common Stockindirect: By Funds | +43,707 | $8.76 | $383k | 4,986,480 | Feb 3, 2025 |
| Jan 31, 2025 | POpen-market purchase Common Stockindirect: By Funds | +11,754 | $8.89 | $104k | 4,998,234 | Feb 3, 2025 |
| Feb 3, 2025 | POpen-market purchase Common Stockindirect: By Funds | +14,562 | $9.22 | $134k | 5,012,796 | Feb 3, 2025 |
Related signals
Other insiders at KalVista Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 35Weak | KalVista Pharmaceuticals, Inc. | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | $120k 7,294 shares | -2% | |
| 22Weak | KalVista Pharmaceuticals, Inc. | Nicole Sweeny Chief Commercial Officer | $51k 3,813 shares | -9% | |
| 23Weak | KalVista Pharmaceuticals, Inc. | Paul K. Audhya CHIEF MEDICAL OFFICER | $71k 5,296 shares | -4% | |
| 36Weak | KalVista Pharmaceuticals, Inc. | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | $147k 10,940 shares | -3% | |
| 22Weak | KalVista Pharmaceuticals, Inc. | Christopher Yea CHIEF DEVELOPMENT OFFICER | $58k 4,331 shares | -2% | |
| 39Weak | KalVista Pharmaceuticals, Inc. | Brian Piekos Chief Financial Officer | $60k 4,471 shares | -30% | |
| 21Weak | KalVista Pharmaceuticals, Inc. | Paul K. Audhya CHIEF MEDICAL OFFICER | $45k 3,075 shares | -2% | |
| 33Weak | KalVista Pharmaceuticals, Inc. | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | $65k 4,466 shares | -1% | |
| 21Weak | KalVista Pharmaceuticals, Inc. | Christopher Yea CHIEF DEVELOPMENT OFFICER | $39k 2,683 shares | -2% | |
| 31Weak | KalVista Pharmaceuticals, Inc. | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | $38k 3,328 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.